<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456286</url>
  </required_header>
  <id_info>
    <org_study_id>TEHYLIC</org_study_id>
    <nct_id>NCT01456286</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension</brief_title>
  <official_title>Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sapropterin (an oral analogue of&#xD;
      tetrahydrobiopterin) could have a role in the treatment of portal hypertension secondary to&#xD;
      liver cirrhosis. Sapropterin or placebo will be given for two weeks in patients with liver&#xD;
      cirrhosis and clinically significant portal hypertension. Systemic and hepatic hemodynamics&#xD;
      studies will be performed at baseline and after the intervention to assess the effect of&#xD;
      sapropterin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension and its complications (variceal bleeding, encephalopathy, spontaneous&#xD;
      bacterial peritonitis, hepatorenal syndrome) are the main cause of death and liver&#xD;
      transplantation in patients with cirrhosis. Diminishing portal hypertension by drugs&#xD;
      (beta-blockers) is associated with a protection in the development of complications from&#xD;
      portal hypertension. For this reason it is important to investigate and develop drugs that&#xD;
      can reduce the portal pressure in liver cirrhosis. Tetrahydrobiopterin has been shown to&#xD;
      decrease portal pressure in animal models of cirrhosis by improving intrahepatic resistance&#xD;
      and by increasing nitric oxide bioavailability (eNOS co-factor). These effects were not&#xD;
      associated to deleterious effects on systemic hemodynamics.&#xD;
&#xD;
      This study aims to test if sapropterin (an oral analogue of tetrahydrobiopterin) can play a&#xD;
      role in the management of portal hypertension. For this, patients with liver cirrhosis and&#xD;
      clinically significant portal hypertension will be randomized to receive sapropterin or&#xD;
      placebo for two weeks. Patients will undergo an hepatic vein catheterization to asses the&#xD;
      hepatic venous pressure gradient (HVPG), and those having and HVPG of 10 mmHg or higher will&#xD;
      be randomized to receive sapropterin or placebo. Swan-Ganz catheterization, systemic&#xD;
      measurements, and hepatic blood flow by indocyanine green method will also be performed.&#xD;
      Patients will receive sapropterin or placebo for two weeks at a dosage of 5 mg/kg/d in the&#xD;
      first week, increasing to 10 mg/kg/d in the second week if there are no adverse events or&#xD;
      intolerance. A second systemic and hepatic hemodynamic study will be performed after 2 weeks&#xD;
      of treatment to assess changes.&#xD;
&#xD;
      Changes in laboratory tests, liver function (Child-Pugh and MELD scores), endothelial&#xD;
      dysfunction and oxidative stress markers (Von Willebrand Factor, Malondialdehyde) will be&#xD;
      monitored during the study. As sapropterin has been never evaluated in cirrhotic patients,&#xD;
      tolerance and adverse effects related to the medication will be registered.&#xD;
&#xD;
      The study will be stratified according to previous beta-blocker therapy (receiving or not&#xD;
      receiving beta-blockers).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hepatic Venous Pressure Gradient</measure>
    <time_frame>2 weeks</time_frame>
    <description>Changes in portal pressure gradient as measured by hepatic vein catheterization, induced by 2 week treatment with sapropterin/placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Sapropterin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg daily first week; 10 mg/kg daily second week of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapropterin</intervention_name>
    <description>two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week</description>
    <arm_group_label>Sapropterin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis of any etiology diagnosed by biopsy or by clinical-imaging data&#xD;
&#xD;
          -  Male or female patients between 18-75 years old in whom hepatic vein catheterization&#xD;
             is indicated.&#xD;
&#xD;
          -  Clinically significant portal hypertension defined by a HVPG ≥ 10 mmHg.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End-stage liver failure defined by one of the following: Prothrombin activity &lt; 40%&#xD;
             and/or Bilirubin &gt; 5 mg/dl.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Concomitant beginning of non-selective beta-blockers (propranolol, nadolol) during the&#xD;
             administration of sapropterin. Beta-blockers are not exclusion criteria if they are on&#xD;
             stable doses in the previous 6 weeks.&#xD;
&#xD;
          -  Treatment with carvedilol or nitrates.&#xD;
&#xD;
          -  Previous TIPS or derivative shunt.&#xD;
&#xD;
          -  Hepatocellular carcinoma exceeding Milan criteria.&#xD;
&#xD;
          -  Spontaneous bacterial peritonitis or any active infection when entering in the study.&#xD;
&#xD;
          -  Portal vein thrombosis or cavernomatosis at ultrasound.&#xD;
&#xD;
          -  Chronic heart failure, respiratory failure or chronic renal failure (Creatinine &gt;2&#xD;
             mg/dl).&#xD;
&#xD;
          -  Previous convulsions or epilepsy.&#xD;
&#xD;
          -  Hypersensibility to sapropterin or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C García-Pagán, MD phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Madrid Community</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>October 1, 2013</last_update_submitted>
  <last_update_submitted_qc>October 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

